A strong moat with a legal shadow
- Sotera's core strength is Sterigenics plus Nordion, a rare mix of sterilization plants and Cobalt-60 supply.
- Q1 2026 revenue was $280.05 million, up 10% year over year, with Sterigenics and Nordion doing most of the work.
- Nelson Labs is the weak spot, with Q1 revenue down 0.7% and segment margin falling to 28.0%.
- Ethylene oxide lawsuits remain the main risk, including about 755 pending Georgia claims tied to the Atlanta facility.
- New CEO Alton Shader gives the company a fresh chance to fix Nelson Labs and set the next sterilization plan.
Good business, hard overhang
Sotera sits in a needed part of healthcare. Many medical devices and drug products must be sterilized before use. Customers do not pick these services lightly, because failure can stop product shipments or create safety issues.
The bull case starts with the link between Sterigenics and Nordion. Sterigenics runs sterilization services. Nordion supplies Cobalt-60, the isotope used in gamma sterilization. That gives Sotera more control over a key input than many rivals have, and Q1 2026 showed pricing power in the main sterilization business.
The bear case is not small. Ethylene oxide, or EO, is a gas used to sterilize products that cannot handle heat or radiation. It has also created a long legal fight over emissions. Sotera paid a $34.0 million Illinois EO settlement in early 2026, and the bigger open question is what happens to the remaining Georgia claims.
The leadership change matters. Alton Shader became CEO effective May 26, 2026, while Michael Petras moved to Executive Chairman. The next year should show whether new leadership can turn Nelson Labs around, push X-ray and other alternatives forward, and reduce the legal cloud.
Paid to make products usable
Sotera makes money by doing work that healthcare companies often cannot skip. A medical device maker may need sterilization, lab testing, and expert advice before a product reaches hospitals. Sotera charges for those services across a product's life, from development through shipping.
Sterigenics is the largest piece. It uses gamma irradiation, EO processing, and E-beam irradiation to sterilize medical devices, drugs, and some food safety products. This business can be sticky because customers must validate their process, which means prove that a specific plant and method works for their product.
Nordion is the supply backbone for gamma sterilization. It sells Cobalt-60 and gamma systems, and it helps support Sterigenics' position. Nelson Labs is different. It provides microbiology, chemistry testing, and advisory work, but recent volume weakness has made it less helpful to growth.
The model breaks if legal costs or new rules eat the cash that the core business produces. In Q1 2026, Sotera still generated $29 million in operating cash flow after the $34.0 million EO settlement payment. That is a good sign, but it does not remove the risk of more settlements or higher environmental spending.
Sterilization, supply, and testing
Sterigenics gamma sterilization
Gamma sterilization uses radiation to sterilize large batches of products. It is helped by Sotera's Nordion supply link.
Sterigenics EO processing
EO can sterilize products that may not work well with heat or some forms of radiation. It is useful, but it is also the center of Sotera's largest legal and regulatory risk.
E-beam and X-ray sterilization
E-beam is already part of the service mix, while a new X-ray facility is going through final qualification. These methods could help reduce long-term dependence on EO.
Nordion Cobalt-60 supply
Nordion supplies Cobalt-60, a key input for gamma sterilization, and sells gamma irradiation systems. Q1 2026 revenue rose 29.0%, helped by Co-60 harvest timing.
Nelson Labs testing and advisory
Nelson Labs tests products and gives technical advice to medical device and pharma customers. It is useful to customers, but Q1 2026 revenue and margins both moved the wrong way.
NO2-based sterilization investment
Sotera is investing in nitrogen dioxide based sterilization technology. This is an option on future demand for alternatives to EO.
Q1 mix still favors sterilization
Segment shares use Q1 2026 net revenues: Sterigenics $186.1 million, Nordion $42.0 million, and Nelson Labs $51.9 million. The mix can move quarter to quarter because Nordion revenue depends partly on Co-60 harvest timing.
What could go wrong
EO litigation keeps draining cash
High impact · High oddsEO lawsuits are the main risk to the stock story. Sotera finalized a $34.0 million settlement for 129 Illinois claims in February 2026. About 450 personal injury claims and 305 property devaluation claims tied to the Atlanta facility remain pending in Georgia.
Nelson Labs fails to recover
Medium impact · Medium oddsNelson Labs turned from a margin help in 2025 into a headwind in Q1 2026. Revenue fell 0.7%, volume and mix fell 6.6%, and segment margin dropped from 31.4% to 28.0%. If this continues, it weakens the case that Sotera can grow beyond core sterilization.
EPA rules force more spending
High impact · Medium oddsEO is useful but closely watched by regulators. The company already expected environmental facility enhancements to be a large capital use in 2025. If the EPA or local regulators tighten rules again, Sotera may need to spend more than planned.
Alternative sterilization adoption is slow
Medium impact · Medium oddsX-ray, E-beam, and NO2 could reduce some long-term EO risk. But customers must test and approve new sterilization methods for each product. If adoption is slow, Sotera remains more exposed to EO legal and regulatory pressure.
Nordion timing looks better than demand
Medium impact · Medium oddsNordion had 29.0% Q1 2026 revenue growth, but the company said a major driver was favorable Co-60 harvest schedule timing. That can make a quarter look stronger than the base trend. Investors should separate timing benefits from repeat demand and pricing.
In one breath
What does Sotera Health do?
Sotera helps healthcare companies sterilize products, source Cobalt-60 for gamma sterilization, and test medical products in labs. Its main customers are medical device, pharmaceutical, and related healthcare companies.
Why is ethylene oxide important to Sotera?
Ethylene oxide, or EO, is a sterilization gas used for products that may not work with other methods. It is also the source of major lawsuits and regulatory risk for Sotera.
Why did Sotera change CEOs in 2026?
The company named Alton Shader as CEO effective May 26, 2026, with Michael Petras moving to Executive Chairman. The key investor question is whether the new CEO changes capital allocation, fixes Nelson Labs, and speeds the shift to alternative sterilization.
Is Sotera mostly a lab testing company?
No. Nelson Labs is meaningful, but Sterigenics is the largest segment by Q1 2026 revenue. The main investment debate is still about sterilization strength versus EO legal risk.